ERBB2 and gastric cancer: However, until today treatment with epidermal growth factor receptor (ERBB2 or Her2/neu) inhibitors remains the only approved first-line targeted tyrosine kinase inhibitor (TKI) therapy [6], and HER2 amplification occurs in only about 8% of GC patients [7].